**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) Composition, comprising a salt of O-acetylsalicylic acid with a basic amino acid, which salt has an average particle size above a particle size of 160 µm and a proportion of more than 60% of the particles having a particle size in a range from 100 to 200 µm in a particle size distribution measured using a Malvern 2600D apparatus under standard conditions, characterized in that the composition additionally comprises a flow improver or ~~and/or~~ is granulated.

2. (currently amended) Composition according to Claim 1, characterized in that it comprises, as flow improver, one or more saccharides ~~, preferably selected from the group consisting of mannitol, sorbitol, xylitol and lactose and their mixtures~~ .

3. (currently amended) Composition according to Claim 2, characterized in that it is dry-granulated ~~, preferably roller compacted~~ .

4. (currently amended) Composition according to claim 1 ~~any of the preceding claims~~, characterized in that the salt has an average particle size above a particle size of 170 µm and a proportion of more than 70% of the particles having a particle size in a range from 100 to 200 µm in a particle size distribution measured using a Malvern 2600D apparatus under standard conditions.

5. (currently amended) Composition according to claim 1 ~~any of the preceding claims~~, characterized in that the basic amino acid is lysine, arginine, histidine, ornithine or diaminobutyric acid ~~, preferably lysine~~ .

6. (currently amended) Composition according to claim 1 ~~any of the preceding claims~~, characterized in that it additionally comprises a proportion of from 5 to 15% by weight of glycine, based on the total amount of O-acetylsalicylate and glycine.

7. (currently amended) Pharmaceutical composition, comprising at least one composition according to claim 1 ~~any of the preceding claims~~.

8. (currently amended) Pharmaceutical composition according to claim 7 ~~the preceding claim~~, characterized in that it is provided as a single-dose solid oral administration form ~~, in particular as a tablet, a chewable tablet, a soluble tablet, an enteric-coated tablet, a capsule or a colon-targeted formulation~~.

9. (currently amended) A pharmaceutical composition as claimed in Claim 7 ~~or 8~~, characterized in that it only comprises water-soluble auxiliaries ~~, preferably flow improvers as set forth in Claim 2~~.

10. (currently amended) Pharmaceutical composition according to claim 7 ~~any of Claims 7 to 9~~, characterized in that it is completely soluble in water.

11. (currently amended) Pharmaceutical according to claim 7 ~~any of Claims 7 to 10~~, characterized in that it comprises one or more further pharmaceutically active compounds ~~, in particular one or more ADP receptor antagonists, GPIIb/IIIa receptor antagonists, phosphodiesterase inhibitors, thrombin receptor antagonists, factor Xa inhibitors, HMG-CoA receptor antagonists and/or calcium antagonists~~ .

12. (currently amended) A method of treating ~~Use of compositions according to any of Claims 1 to 6 for preparing a pharmaceutical for treating~~ disorders of a rheumatic type,

arthritis, neuralgia, myalgia or ~~and/or~~ migraine , comprising administering to a patient in need thereof an effective amount of a composition of claim 1 .

13. (currently amended) A method of treating ~~Use of compositions according to any of Claims 1 to 6 for preparing a pharmaceutical for~~ treating ischaemic heart diseases, stroke, angina pectoris, myocardial infarction, bypass operations, PTCA or ~~and/or~~ stent implants , comprising administering to a patient in need thereof an effective amount of a composition of claim 1 .

14. (currently amended) A method ~~Use of compositions according to any of Claims 1 to 6 for preparing a pharmaceutical~~ for stimulating the immune system of HIV patients, for tumour prophylaxis, for slowing down the cognitive deterioration associated with dementia, for inhibiting the formation of gallstones or ~~and/or~~ for treating diabetic disorders , comprising administering to a patient in need thereof an effective amount of a composition of claim 1 .

15. (new) The pharmaceutical composition of claim 8, wherein the composition is a tablet, a chewable tablet, a soluble tablet, an enteric-coated tablet, a capsule or a colon-targeted formulation.

16. (new) The pharmaceutical of claim 11, wherein the pharmaceutically active compound is selected from ADP receptor antagonists, GPIIb/IIIa receptor antagonists, phosphodiesterase inhibitors, thrombin receptor antagonists, factor Xa inhibitors, HMG-CoA receptor antagonists and calcium antagonists.

17. (new) The composition of claim 2, wherein the flow improver is selected from the group consisting of mannitol, sorbitol, xylitol, and lactose, and a mixture thereof.

18. (new) The composition of claim 3, wherein the composition is roller-compacted.

19. (new) The pharmaceutical composition of claim 9, wherein the water-soluble auxiliary is a flow improver selected from the group consisting of mannitol, sorbitol, xylitol, and lactose, and a mixture thereof.